Patent classifications
C07C229/48
Cyclic vinylogous amides as bromodomain inhibitors
Cyclic vinylogous amides of Formula I are disclosed ##STR00001##
The compounds are useful for treating diseases that arise from inappropriate activity of proteins containing an acetyl-lysine. The compositions comprise a genus of cyclic vinylogous amides that are inhibitors of bromodomain.
Cyclic vinylogous amides as bromodomain inhibitors
Cyclic vinylogous amides of Formula I are disclosed ##STR00001##
The compounds are useful for treating diseases that arise from inappropriate activity of proteins containing an acetyl-lysine. The compositions comprise a genus of cyclic vinylogous amides that are inhibitors of bromodomain.
BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
Process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols
The present invention relates to a novel process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols, and to novel intermediates or starting compounds that are passed through or used in the process according to the invention.
Process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols
The present invention relates to a novel process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols, and to novel intermediates or starting compounds that are passed through or used in the process according to the invention.
Fused (hetero)cyclic compounds as S1P modulators
The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
Fused (hetero)cyclic compounds as S1P modulators
The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
Compounds that are S1P modulating agents and/or ATX modulating agents
Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
Compounds that are S1P modulating agents and/or ATX modulating agents
Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).